Abstract
Anti-CCP (cyclic citrullinated peptide) is considered the most useful laboratory tool in the diagnosis of rheumatoid arthritis (RA). Some authors have also found this autoantibody in patients with scleroderma (SSc). The study aimed to investigate the prevalence of anti-CCP antibodies in SSc patients from Southern Brazil and their association with clinical and serological profile of the disease. We studied 76 patients with SSc and 100 healthy volunteers for presence of anti-CCP. SSc patients charts were reviewed for clinical and laboratory data. In the SSc group, the diffuse form was present in 20.5%; 62.8% had the limited form; 14.1% had overlap with systemic lupus or polymyositis and 2.5% had SSc sine scleroderma. Anti-CCP was found in nine of 78 (11.5%) SSc patients and in one of 100 healthy volunteers (p = 0.0054). No relationship was found with arthritis, skin Rodnan m score, esophageal dysmotility, myocarditis, pulmonary hypertension and lung fibrosis. Positive association was observed with arthralgias (p = 0.02). Also, no relationship was noted with the presence of anti-centromere antibodies, anti-Scl-70, anti-RNP or rheumatoid factor. Anti-CCP are more common in SSc patients than in controls. Arthralgias but not arthritis or rheumatoid factor are more frequent in anti-CCP positive patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Misra R, Darton K, Jewkes RF, Black CM, Maini RN (1995) Arthritis in scleroderma. Br J Rheumatol 34:831–837
La Montagna G, Solano A, Capurro V, Malesci D, Valentini G (2005) The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiol 34:35–41
Ingegnoli F, Galbiati V, Zeni S et al (2007) Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol 26:510–514
Blocka KN, Basset LW, Furst DE, Clements PJ, Paulus HE (1981) The arthropathy of advanced progressive systemic sclerosis. A radiographic survey. Arthritis Rheum 24:874–884
Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D et al (2008) Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 58:3000–3008
Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808
Cui J, Taylor KE, Destefano AL, Criswell LA, Izmailova ES, Parker A et al (2009) Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis. J Mol Med 15:136–143
Santiago M, Baron M, Miyachi K et al (2008) A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP-3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 27:77–83
Moryta Y, Muro K, Sugiura K, Tomita Y (2008) Anti citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol 26:542–547
Subcommitee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590
Furst DE, Clements PJ, Wong WK, Mayes MD, Wigley F, White BE et al (2001) Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. Rheumatol 40:615–622
Denton CP, Black CM (2003) Pulmonary hypertension in systemic sclerosis. Rheuma Dis Clin N Am 29:335–349
Akenson A, Fiori G, Krieg T, van den Hoogen FHJ, Seibold JR (2003) The assessment of the patient with systemic sclerosis. The assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 21(3 Suppl 29):S5–S8
Bassotti G, Battaglia E, Debernardi V, Germani U, Quiriconi F, Dughera L et al (1997) Esophageal dysfunction in scleroderma. Arthritis Rheum 40:2252–2259
Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167
Szücs G, Szekanecz Z, Zilahi E et al (2007) Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetics serological and clinical entity. Rheumatology 46:989–993
Zimmermann C, Steiner G, Skriner K, Hassfeld W, Petera P, Smoles JS (1998) The concurrence of rheumatoid arthritis and limited systemic sclerosis. Arthritis Rheum 41:1936–1945
Rodnan GP (1962) The nature of joint involvement in progressive systemic sclerosis (diffuse scleroderma). Ann Inter Med 56:422–439
Goeldner I, Skare TL, de Messias Reason IT, Nisihara RM, Silva MB, Utiyama SR (2010) Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology 49:1590–1593
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Polimeni, M., Feniman, D., Skare, T.S. et al. Anti-cyclic citrullinated peptide antibodies in scleroderma patients. Clin Rheumatol 31, 877–880 (2012). https://doi.org/10.1007/s10067-011-1930-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1930-z